Cargando…

Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development

SIMPLE SUMMARY: Neuropilin-1 is a co-receptor for semaphorins and vascular endothelial growth factor family members. Neuropilin-1 can be expressed on tumor cells, tumor-infiltrating myeloid and lymphoid cells and has been linked to a tumor-promoting environment. We investigated nanobodies (Nbs) targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Vlaeminck, Yannick, Bonelli, Stefano, Awad, Robin Maximilian, Dewilde, Maarten, Rizzolio, Sabrina, Lecocq, Quentin, Bolli, Evangelia, Santos, Ana Rita, Laoui, Damya, Schoonooghe, Steve, Tamagnone, Luca, Goyvaerts, Cleo, Mazzone, Massimiliano, Breckpot, Karine, Van Ginderachter, Jo A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760077/ https://www.ncbi.nlm.nih.gov/pubmed/33266104 http://dx.doi.org/10.3390/cancers12123582

Ejemplares similares

Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019)

Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
por: Lecocq, Quentin, et al.
Publicado: (2019)

Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
por: Awad, Robin Maximilian, et al.
Publicado: (2018)

Cancer-Associated Myeloid Regulatory Cells
por: De Vlaeminck, Yannick, et al.
Publicado: (2016)

Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
por: Lecocq, Quentin, et al.
Publicado: (2021)

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines
por: Goyvaerts, Cleo, et al.
Publicado: (2015)

The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
por: Goyvaerts, Cleo, et al.
Publicado: (2018)

Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade
por: Awad, Robin Maximilian, et al.
Publicado: (2021)

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
por: Ertveldt, Thomas, et al.
Publicado: (2022)

Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry
por: Chigoho, Dora Mugoli, et al.
Publicado: (2021)

In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4(+) T cells
por: Awad, Robin Maximilian, et al.
Publicado: (2023)

Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma
por: De Beck, Lien, et al.
Publicado: (2022)

Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8(+) T cell and iNKT cell activating mRNA vaccine
por: Ertveldt, Thomas, et al.
Publicado: (2023)

Development and Characterization of Nanobodies Targeting the Kupffer Cell
por: Zheng, Fang, et al.
Publicado: (2021)

TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy
por: De Ridder, Kirsten, et al.
Publicado: (2022)

Hypoxia and tumor-associated macrophages: A deadly alliance in support of tumor progression
por: Van Overmeire, Eva, et al.
Publicado: (2014)

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
por: Broos, Katrijn, et al.
Publicado: (2017)

The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity
por: Laoui, Damya, et al.
Publicado: (2016)

Neuropilins Controlling Cancer Therapy Responsiveness
por: Napolitano, Virginia, et al.
Publicado: (2019)

Immunogenicity of targeted lentivectors
por: Goyvaerts, Cleo, et al.
Publicado: (2014)

Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer
por: Lecocq, Q., et al.
Publicado: (2021)

Mechanisms Driving Macrophage Diversity and Specialization in Distinct Tumor Microenvironments and Parallelisms with Other Tissues
por: Van Overmeire, Eva, et al.
Publicado: (2014)

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression
por: Laoui, Damya, et al.
Publicado: (2014)

Junctional adhesion molecule-A is dispensable for myeloid cell recruitment and diversification in the tumor microenvironment
por: Kiss, Máté, et al.
Publicado: (2022)

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
por: Broos, Katrijn, et al.
Publicado: (2019)

The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
por: Lecocq, Quentin, et al.
Publicado: (2020)

Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
por: Bridoux, Jessica, et al.
Publicado: (2020)

The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology
por: Vanmeerbeek, Isaure, et al.
Publicado: (2022)

Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels
por: Scherger, Maximilian, et al.
Publicado: (2020)

IFNγ signaling response in peripheral blood monocytes: A new prognostic biomarker for breast cancer?
por: Deschoemaeker, Sofie, et al.
Publicado: (2020)

Targeted Repolarization of Tumor‐Associated Macrophages via Imidazoquinoline‐Linked Nanobodies
por: Bolli, Evangelia, et al.
Publicado: (2021)

Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells
por: Goyvaerts, C, et al.
Publicado: (2012)

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
por: Zeven, Katty, et al.
Publicado: (2023)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Immunogenicity Risk Profile of Nanobodies
por: Ackaert, Chloé, et al.
Publicado: (2021)

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon
por: Broos, Katrijn, et al.
Publicado: (2016)

In Vivo Inhibition of c-MYC in Myeloid Cells Impairs Tumor-Associated Macrophage Maturation and Pro-Tumoral Activities
por: Pello, Oscar M., et al.
Publicado: (2012)

In vitro combination therapy of pathologic angiogenesis using anti-vascular endothelial growth factor and anti-neuropilin-1 nanobodies
por: Mohseni, Nastaran, et al.
Publicado: (2020)

Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting
por: Erreni, Marco, et al.
Publicado: (2023)

Targeting the tumor microenvironment to enhance antitumor immune responses
por: Van der Jeught, Kevin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_858j6t6f0g7j06l7n63gkjfcav